Patients with decreased m6A modification depicted higher mutations of cancer associated genes such as Cadherin 1 (CDH1), GLI3, Ras homolog gene family, member A (RHOA), Mucin 6, Oligomeric Mucus/Gel-Forming (MUC6), and TP53), well as exhibited worse clinical outcomes. Here, TP53 is linked to cancer.